宫颈癌化疗药物耐药性逆转分子机制
The Molecular Mechanism for Reversing Chemotherapy Drug Resistance in Cervical Cancer
DOI: 10.12677/acm.2025.15123392, PDF,    科研立项经费支持
作者: 周笑跃, 刘文康, 姜向阳*, 梁汝棋：西安医学院研究生工作部，陕西 西安
关键词: 宫颈癌；化疗耐药；逆转；分子机制；Cervical Cancer； Chemotherapy Resistance； Reversal； Molecular Mechanism
摘要: 宫颈癌是常见的女性生殖系统恶性肿瘤之一，早期筛查以及预防性注射HPV疫苗如今虽有一定进展，但宫颈癌的发病率和死亡率仍呈上升趋势且呈年轻化。紫杉醇与顺铂属于宫颈癌治疗的一线化疗药物，但其易产生化疗耐药，严重影响患者治疗效果及预后，因此了解宫颈癌化疗药物耐药性逆转分子机制具有相当重要意义，以期为攻克宫颈癌化疗耐药提供新的临床诊疗思路。
Abstract: Cervical cancer is one of the common malignant tumors of the female reproductive system. Although there have been certain advancements in early screening and preventive HPV vaccination, the incidence and mortality rates of cervical cancer are still on the rise and showing a trend towards younger patients. Paclitaxel and cisplatin are first-line chemotherapy drugs for the treatment of cervical cancer, but they are prone to chemotherapy resistance, which seriously affects the treatment effect and prognosis of patients. Therefore, understanding the molecular mechanism of chemotherapy drug resistance reversal in cervical cancer is of great significance, with the aim of providing new clinical treatment ideas for overcoming chemotherapy resistance in cervical cancer.
文章引用：周笑跃, 刘文康, 姜向阳, 梁汝棋. 宫颈癌化疗药物耐药性逆转分子机制[J]. 临床医学进展, 2025, 15(12): 161-169. https://doi.org/10.12677/acm.2025.15123392

参考文献

[1] Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R.L., Soerjomataram, I., et al. (2024) Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 74, 229-263. [Google Scholar] [CrossRef] [PubMed]
[2] Ley, C., Bauer, H.M., Reingold, A., et al. (1991) Determinants of Genital Human Papillomavirus Infection in Young Women. Journal of the National Cancer Institute, 83, 997-1003.
[3] Lorusso, D., Petrelli, F., Coinu, A., Raspagliesi, F. and Barni, S. (2014) A Systematic Review Comparing Cisplatin and Carboplatin Plus Paclitaxel-Based Chemotherapy for Recurrent or Metastatic Cervical Cancer. Gynecologic Oncology, 133, 117-123. [Google Scholar] [CrossRef] [PubMed]
[4] Park, D.C., Suh, M.J. and Yeo, S.G. (2009) Neoadjuvant Paclitaxel and Cisplatin in Uterine Cervical Cancer. International Journal of Gynecological Cancer, 19, 943-947. [Google Scholar] [CrossRef] [PubMed]
[5] Klyuchko, K.O. and Gargin, V.V. (2020) Influence of Neoadjuvant Chemoradiotherapy for Locally Advanced Cervical Cancer. Polski Merkuriusz Lekarski, 48, 406-409.
[6] 刘红, 张国楠. 宫颈癌化疗耐药相关问题[J]. 中国实用妇科与产科杂志, 2015, 31(3): 198-201.
[7] 杜春双, 马亚妮, 王帅, 张飞, 张洁, 桑广健. 左旋紫草素对顺铂耐药人宫颈癌HeLa细胞的逆转作用研究[J]. 中国药房, 2020, 31(15): 1867-1873.
[8] Zhang, T. and Xiaohan, C. (2025) Unveiling the Role of JAK2/STAT3 Signaling in Chemoresistance of Gynecological Cancers: From Mechanisms to Therapeutic Implications. Critical Reviews in Oncology/Hematology, 211, Article 104712. [Google Scholar] [CrossRef] [PubMed]
[9] Bhattacharjee, R., Dey, T., Kumar, L., Kar, S., Sarkar, R., Ghorai, M., et al. (2022) Cellular Landscaping of Cisplatin Resistance in Cervical Cancer. Biomedicine & Pharmacotherapy, 153, Article 113345. [Google Scholar] [CrossRef] [PubMed]
[10] Martinho, O., Pinto, F., Granja, S., Miranda-Gonçalves, V., Moreira, M.A.R., Ribeiro, L.F.J., et al. (2013) RKIP Inhibition in Cervical Cancer Is Associated with Higher Tumor Aggressive Behavior and Resistance to Cisplatin Therapy. PLOS ONE, 8, e59104. [Google Scholar] [CrossRef] [PubMed]
[11] Luo, F., Wen, Y., Zhou, H. and Li, Z. (2020) Roles of Long Non-Coding RNAs in Cervical Cancer. Life Sciences, 256, Article 117981. [Google Scholar] [CrossRef] [PubMed]
[12] Zhang, W., Wu, Q., Liu, Y., Wang, X., Ma, C. and Zhu, W. (2022) LncRNA HOTAIR Promotes Chemoresistance by Facilitating Epithelial to Mesenchymal Transition through miR-29b/PTEN/PI3K Signaling in Cervical Cancer. Cells Tissues Organs, 211, 16-29. [Google Scholar] [CrossRef] [PubMed]
[13] Wang, Q., Cheng, N., Li, X., Pan, H., Li, C., Ren, S., et al. (2017) Correlation of Long Non-Coding RNA h19 Expression with Cisplatin-Resistance and Clinical Outcome in Lung Adenocarcinoma. Oncotarget, 8, 2558-2567. [Google Scholar] [CrossRef] [PubMed]
[14] Zhou, C., Yi, C., Yi, Y., Qin, W., Yan, Y., Dong, X., et al. (2020) LncRNA PVT1 Promotes Gemcitabine Resistance of Pancreatic Cancer via Activating Wnt/β-Catenin and Autophagy Pathway through Modulating the miR-619-5p/Pygo2 and miR-619-5p/ATG14 Axes. Molecular Cancer, 19, Article No. 118. [Google Scholar] [CrossRef] [PubMed]
[15] 王程, 朱逸飞, 郑世康, 等. 长链非编码RNA pot1-as1在宫颈癌顺铂耐药中的作用研究[J]. 解放军医学院学报, 2024, 45(3): 302-309.
[16] Wen, K., Wang, L., Su, H., Yu, L., Zhang, S., Wei, M., et al. (2025) Development of a m6A-and Ferroptosis-Related LncRNA Signature for Forecasting Prognosis and Treatment Response in Cervical Cancer. BMC Cancer, 25, Article No. 580. [Google Scholar] [CrossRef] [PubMed]
[17] Wang, X.W. and Zhang, W. (2019) Long Non-Coding RNA Cancer Susceptibility Candidate 2 Inhibits the Cell Proliferation, Invasion and Angiogenesis of Cervical Cancer through the MAPK Pathway. European Review for Medical and Pharmacological Sciences, 23, 3261-3269.
[18] Feng, Y., Zou, W., Hu, C., Li, G., Zhou, S., He, Y., et al. (2017) Modulation of CASC2/miR-21/PTEN Pathway Sensitizes Cervical Cancer to Cisplatin. Archives of Biochemistry and Biophysics, 623, 20-30. [Google Scholar] [CrossRef] [PubMed]
[19] Jin, S., Wang, W., Xu, X., Yu, Z., Feng, Z., Xie, J., et al. (2024) miR-34b-3p-Mediated Regulation of STC2 and FN1 Enhances Chemosensitivity and Inhibits Proliferation in Cervical Cancer. Acta Biochimica et Biophysica Sinica, 56, 740-752. [Google Scholar] [CrossRef] [PubMed]
[20] Li, Y., Zhou, Z., Qu, J., Gong, P., Wei, Y. and Sun, Y. (2024) Role of MicroRNA-4739 in Enhancing Cisplatin Chemosensitivity by Negative Regulation of RHBDD2 in Human Cervical Cancer Cells. Cellular & Molecular Biology Letters, 29, Article No. 20. [Google Scholar] [CrossRef] [PubMed]
[21] Nishi, H., Ono, M., Ohno, S., Yamanaka, Z., Sasaki, T., Ohyashiki, K., et al. (2023) Hypoxia-Induced Paclitaxel Resistance in Cervical Cancer Modulated by miR-100 Targeting of USP15. Gynecologic Oncology Reports, 45, Article 101138. [Google Scholar] [CrossRef] [PubMed]
[22] 王虎年, 柴克霞, 张莉. 铁死亡通路中ACSL4、LPCAT3蛋白表达在特发性炎性肌病中的研究[J]. 系统医学, 2023, 8(11): 190-193+198.
[23] Tang, D. and Kroemer, G. (2020) Ferroptosis. Current Biology, 30, R1292-R1297. [Google Scholar] [CrossRef] [PubMed]
[24] Yang, X., Yin, F., Liu, Q., Ma, Y., Zhang, H., Guo, P., et al. (2022) Ferroptosis-related Genes Identify Tumor Immune Microenvironment Characterization for the Prediction of Prognosis in Cervical Cancer. Annals of Translational Medicine, 10, 123-123. [Google Scholar] [CrossRef] [PubMed]
[25] Köberle, B. and Schoch, S. (2021) Platinum Complexes in Colorectal Cancer and Other Solid Tumors. Cancers, 13, Article No. 2073. [Google Scholar] [CrossRef] [PubMed]
[26] Lamberti, M.J., Nigro, A., Casolaro, V., Rumie Vittar, N.B. and Dal Col, J. (2021) Damage-Associated Molecular Patterns Modulation by MicroRNA: Relevance on Immunogenic Cell Death and Cancer Treatment Outcome. Cancers, 13, Article No. 2566. [Google Scholar] [CrossRef] [PubMed]
[27] Yu, S., Wang, Y., Jing, L., Claret, F.X., Li, Q., Tian, T., et al. (2017) Autophagy in the “Inflammation-Carcinogenesis” Pathway of Liver and HCC Immunotherapy. Cancer Letters, 411, 82-89. [Google Scholar] [CrossRef] [PubMed]
[28] 张鹏, 葛亮, 孔令国, 等. 咪达唑仑通过调节Nrf2/HO-1信号通路对宫颈癌细胞铁死亡的作用及机制研究[J]. 实用医学杂志, 2023, 39(14): 1740-1745.
[29] Qi, X.L., Fu, Y.P., Sheng, J., Zhang, M., Zhang, M., Wang, Y., et al. (2021) A Novel Ferroptosis-Related Gene Signature for Predicting Outcomes in Cervical Cancer. Bioengineered, 12, 1813-1825. [Google Scholar] [CrossRef] [PubMed]
[30] Yong, X., Zhang, Y., Tang, H., Hu, H., Song, R. and Wu, Q. (2024) CDKN2A Inhibited Ferroptosis through Activating JAK2/STAT3 Pathway to Modulate Cisplatin Resistance in Cervical Squamous Cell Carcinoma. Anti-Cancer Drugs, 35, 698-708. [Google Scholar] [CrossRef] [PubMed]
[31] Zhang, X.F., Sui, S.Y., Wang, L.L., Li, H., Zhang, L., Xu, S., et al. (2020) Inhibition of Tumor Propellant Glutathione Peroxidase 4 Induces Ferroptosis in Cancer Cells and Enhances Anticancer Effect of Cisplatin. Journal of Cellular Physiology, 235, 3425-3437. [Google Scholar] [CrossRef] [PubMed]
[32] Yun, C.W. and Lee, S.H. (2018) The Roles of Autophagy in Cancer. International Journal of Molecular Sciences, 19, Article 3466. [Google Scholar] [CrossRef] [PubMed]
[33] Yun, C.W., Jeon, J., Go, G., Lee, J.H. and Lee, S.H. (2020) The Dual Role of Autophagy in Cancer Development and a Therapeutic Strategy for Cancer by Targeting Autophagy. International Journal of Molecular Sciences, 22, Article 179. [Google Scholar] [CrossRef] [PubMed]
[34] Wang, Y., Shen, F., Zhou, J., Fang, Y., Qi, Y. and Chen, Y. (2022) Overexpression of ARHI Increases the Sensitivity of Cervical Cancer Cells to Paclitaxel through Inducing Apoptosis and Autophagy. Drug Development Research, 83, 142-149. [Google Scholar] [CrossRef] [PubMed]
[35] 高朋, 徐丹丹, 张斌, 等. 氯喹对人宫颈癌细胞系HeLa增殖、凋亡及自噬的影响[J]. 基础医学与临床, 2023, 43(10): 1512-1517.
[36] 杨铠菲, 朱静格, 张洋洋, 等. 索拉菲尼诱导的细胞凋亡和自噬对HeLa细胞耐药性的影响[J]. 基础医学与临床, 2024, 44(4): 467-473.
[37] Mubthasima, P.P., Singh, S.A. and Kannan, A. (2024) Sesamol-Mediated Targeting of EPHA2 Sensitises Cervical Cancer for Cisplatin Treatment by Regulating Mitochondrial Dynamics, Autophagy, and Mitophagy. Molecular Biology Reports, 51, Article No. 949. [Google Scholar] [CrossRef] [PubMed]
[38] Moore, G., Annett, S., McClements, L. and Robson, T. (2020) Top Notch Targeting Strategies in Cancer: A Detailed Overview of Recent Insights and Current Perspectives. Cells, 9, Article 1503. [Google Scholar] [CrossRef] [PubMed]
[39] Wang, M., Qiu, R., Yu, S.R., et al. (2019) Paclitaxel-Resistant Gastric Cancer MGC-803 Cells Promote Epithelial-to-Mesenchymal Transition and Chemoresistance in Paclitaxel-Sensitive Cells via Exosomal Delivery of miR-155-5p. International Journal of Oncology, 54, 326-338.
[40] Sun, T., Zhang, D., Wang, Z., Zhao, B., Li, Y., Sun, X., et al. (2021) Inhibition of the Notch Signaling Pathway Overcomes Resistance of Cervical Cancer Cells to Paclitaxel through Retardation of the Epithelial-Mesenchymal Transition Process. Environmental Toxicology, 36, 1758-1764. [Google Scholar] [CrossRef] [PubMed]
[41] 李平. KAT6B促进宫颈癌恶性生物学行为的作用及其分子机制研究[D]: [博士学位论文]. 苏州: 苏州大学, 2019.
[42] 陆菁菁. miR-487b靶向负调控KAT6B在宫颈癌进展中的作用机制研究[D]: [硕士学位论文]. 镇江: 江苏大学, 2020.
[43] Mou, J., Zheng, W., Wei, D., Li, D., Fan, R. and Tang, Q. (2023) CD200-CD200R Affects Cisplatin and Paclitaxel Sensitivity by Regulating Cathepsin K-Mediated P65 NF-κB Signaling in Cervical Cancer. Heliyon, 9, e19220. [Google Scholar] [CrossRef] [PubMed]
[44] Shen, N.N., Lin, J.H. and Liu, P.P. (2023) EBF1 Promotes the Sensitivity of Cervical Cancer Cells to Cisplatin via Activating FBN1 Transcription. Молекулярная биология, 57, 503-504. [Google Scholar] [CrossRef] 
[45] Yokosuka, T., Takamatsu, M., Kobayashi-Imanishi, W., Hashimoto-Tane, A., Azuma, M. and Saito, T. (2012) Programmed Cell Death 1 Forms Negative Costimulatory Microclusters That Directly Inhibit T Cell Receptor Signaling by Recruiting Phosphatase SHP2. Journal of Experimental Medicine, 209, 1201-1217. [Google Scholar] [CrossRef] [PubMed]
[46] 徐月, 田永巍, 李宁. PD-1/pd-l1抑制剂联合化疗对晚期宫颈癌的疗效及预后分析[J]. 实用癌症杂志, 2024, 39(7): 1167-1170.
[47] Chen, J., Jiang, C.C., Jin, L. and Zhang, X.D. (2016) Regulation of PD-L1: A Novel Role of Pro-Survival Signalling in Cancer. Annals of Oncology, 27, 409-416. [Google Scholar] [CrossRef] [PubMed]
[48] Zhang, L., Zhao, Y., Tu, Q., Xue, X., Zhu, X. and Zhao, K. (2021) The Roles of Programmed Cell Death Ligand-1/ Programmed Cell Death-1 (PD-L1/PD-1) in HPV-Induced Cervical Cancer and Potential for Their Use in Blockade Therapy. Current Medicinal Chemistry, 28, 893-909. [Google Scholar] [CrossRef] [PubMed]
[49] Zhu, Z., Nie, X., Deng, L., Ding, J., Chen, J., Zhu, J., et al. (2024) Regulation of Cervical Cancer via G15-Mediated Inhibition of G Protein-Coupled Estrogen Receptor. Anti-Cancer Drugs, 35, 817-829. [Google Scholar] [CrossRef] [PubMed]
[50] Cory, T.J., He, H., Winchester, L.C., Kumar, S. and Fletcher, C.V. (2016) Alterations in P-Glycoprotein Expression and Function between Macrophage Subsets. Pharmaceutical Research, 33, 2713-2721. [Google Scholar] [CrossRef] [PubMed]
[51] Roy, M. and Mukherjee, S. (2014) Reversal of Resistance towards Cisplatin by Curcumin in Cervical Cancer Cells. Asian Pacific Journal of Cancer Prevention, 15, 1403-1410. [Google Scholar] [CrossRef] [PubMed]
[52] 赵林, 刘四清, 汪强. 星形孢菌素通过PI3K/Akt信号途径影响人宫颈癌细胞增殖与侵袭能力的研究[J]. 临床和实验医学杂志, 2018, 17(1): 47-50.
[53] Liu, Z., Yang, Z. and Ablise, M. (2024) Design and Synthesis of Novel Imidazole-Chalcone Derivatives as Microtubule Protein Polymerization Inhibitors to Treat Cervical Cancer and Reverse Cisplatin Resistance. Bioorganic Chemistry, 147, Article 107310. [Google Scholar] [CrossRef] [PubMed]
[54] Tang, Q., Xu, A., Yang, Y., Zhang, Y. and Sun, J. (2023) FOXM1 Contributes to Chemotherapy Sensitivity in Cervical Cancer by Regulating TTK. Discovery Medicine, 35, 208-220. [Google Scholar] [CrossRef] [PubMed]
[55] Chen, Z., Xiao, Z., Tian, W., Li, Z. and Wu, T. (2023) Two Enhances the Cisplatin Sensitivity of Cervical Cancer Cells via Suppression of C-MET Expression. Iranian Journal of Public Health, 52, 1476-1486. [Google Scholar] [CrossRef] [PubMed]

为你推荐